Purple Biotech Ltd (PPBT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PPBT Stock Price Chart Interactive Chart >
PPBT Price/Volume Stats
| Current price | $1.89 | 52-week high | $4.28 |
| Prev. close | $1.81 | 52-week low | $1.32 |
| Day low | $1.73 | Volume | 74,800 |
| Day high | $2.00 | Avg. volume | 46,022 |
| 50-day MA | $1.66 | Dividend yield | N/A |
| 200-day MA | $2.25 | Market Cap | 33.24M |
Purple Biotech Ltd (PPBT) Company Bio
Purple Biotech Ltd operates as a pharmaceutical company. The Company discovers and develops medicines, drugs, and other pharmaceutical products for the treatment of osteoarthritis pain and hypertension. Purple Biotech serves customers globally.
Latest PPBT News From Around the Web
Below are the latest news stories about PURPLE BIOTECH LTD that investors may wish to consider to help them evaluate PPBT as an investment opportunity.
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer MetastasisData demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it is |
Purple Biotech to Present at the Jefferies London Healthcare ConferenceREHOVOT, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that Gil Efron, Chief Executive Officer of Purple Biotech, and Fabien Sebille, Chief Business Officer, will present a corporate overview of the Co |
Purple Biotech Reports Third Quarter 2022 Financial ResultsWell capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter ended September 30, 2022 |
Purple Biotech Appoints Lior Fhima as Chief Financial OfficerSeasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Lior Fhima, CPA, MBA, as Chief Financial Officer of the Company. Mr. Fhima brings deep |
Purple Biotech (PPBT) Gets a Buy from H.C. WainwrightIn a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on Purple Biotech (PPBT - Research Report) and a price target of $7.00. The company's shares closed last Friday at $1.98.According to TipRanks, Bodnar is an analyst with an average return of -11.9% and a 24.32% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Context Therapeutics, and Dice Therapeutics.Purple Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.See the top stocks recommended by analysts >>The company has a one-year high of $4.75 and a one-year low of $1.83. |
PPBT Price Returns
| 1-mo | 36.96% |
| 3-mo | -9.57% |
| 6-mo | -24.70% |
| 1-year | -27.31% |
| 3-year | -74.01% |
| 5-year | N/A |
| YTD | 36.96% |
| 2022 | -64.52% |
| 2021 | 2.10% |
| 2020 | -51.13% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...